Pharmacovigilance and ADR Reporting
Adverse reaction monitoring and reporting by the drug safety team Egypt’s pharmaceutical companies trust most, during clinical trials and after launch.
Every adverse reaction report is a chance to protect patients. Handling each one carefully, and on time, is the heart of pharmacovigilance.
In clinical trials
We build safety reporting into your study from day one. Our team reviews adverse events as they are reported by sites, assesses serious adverse events and reports them to the sponsor, the ethics committees and the Egyptian Drug Authority within the required timelines, and prepares the development safety update reports.
After launch
For marketed products, we receive reports from healthcare professionals, patients, the literature and your partners, then validate, code, assess and submit each case in ICH E2B (R3) format. Cases are managed in Vigipx, Egypt’s number one safety database, so every report is traceable from receipt to submission.
Contact us to talk about your project.

